Logotype for SELLAS Life Sciences Group Inc

SELLAS Life Sciences Group (SLS) Corporate presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for SELLAS Life Sciences Group Inc

Corporate presentation summary

17 Nov, 2026

Pipeline overview

  • Two clinical-stage assets target AML: GPS, a WT1-directed immunotherapy, and SLS009 (tambiciclib), a selective CDK9 inhibitor.

  • GPS targets WT1, expressed in ~97% of AML patients, and is designed to elicit CD4+ and CD8+ responses across ~90% of human HLA types.

  • SLS009 showed 95% CDK9 suppression with limited off-target suppression; its development also explores hematologic and solid tumors.

GPS clinical program

  • In the Phase 2 CR2 AML study, median OS was 21.0 months with GPS vs 5.4 months with standard of care (p<0.02); median relapse-free survival was 10.5 vs 4.3 months.

  • In the Phase 3 REGAL trial, the January 2025 interim review found potential efficacy and supported continuation; 72 of 80 events had occurred as of Dec. 26, 2025, with final analysis planned at 80 events.

  • REGAL compares GPS with best available therapy in AML CR2/CRp2 or later remission among patients unable or ineligible for allogeneic transplant; primary endpoint is OS.

  • In relapsed/refractory ovarian cancer, GPS plus pembrolizumab showed 50.1% disease control, median PFS of 12 weeks and median OS of 18.4 months at 14.4-month median follow-up.

  • In relapsed/refractory mesothelioma, GPS plus nivolumab produced median OS of 70.3 weeks in nine combination-treated patients; median PFS was 11.9 weeks in all 10 patients.

SLS009 clinical program

  • Phase 2 SLS009 plus azacitidine/venetoclax met all primary endpoints; the selected regimen was 30 mg twice weekly, with no dose-limiting toxicities or treatment-related grade 3+ toxicities reported.

  • At 30 mg twice weekly, ORR was 41% across r/r AML cohorts, 44% in AML with myelodysplasia-related changes and 50% in AML-MR with M4/M5 features.

  • At 30 mg twice weekly, median OS was 8.8 months across r/r AML and 8.9 months in r/r AML-MR patients, versus a stated historical benchmark of 2.4 months for r/r AML.

  • ASH 2025 expansion data showed 44% ORR across AML-MR cohorts and 58% ORR among patients with one prior line of therapy.

  • In a Phase 1 lymphoma cohort, SLS009 showed a 14.7% clinical response rate overall, 35.3% disease control and 36.4% clinical response in PTCL; RP2D was 100 mg once weekly.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from SELLAS Life Sciences Group